653 related articles for article (PubMed ID: 32436428)
1. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.
Zhao Y; Zhou X
Immunotherapy; 2020 Jun; 12(9):653-664. PubMed ID: 32436428
[TBL] [Abstract][Full Text] [Related]
2. CAR-NK cells: A promising cellular immunotherapy for cancer.
Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges.
Kong JC; Sa'ad MA; Vijayan HM; Ravichandran M; Balakrishnan V; Tham SK; Tye GJ
Front Immunol; 2024; 15():1384039. PubMed ID: 38726000
[TBL] [Abstract][Full Text] [Related]
4. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
Yilmaz A; Cui H; Caligiuri MA; Yu J
J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
[TBL] [Abstract][Full Text] [Related]
6. Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy.
Zhang J; Zheng H; Diao Y
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646574
[TBL] [Abstract][Full Text] [Related]
7. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
[TBL] [Abstract][Full Text] [Related]
9. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Rafei H; Daher M; Rezvani K
Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
Mehta RS; Rezvani K
Front Immunol; 2018; 9():283. PubMed ID: 29497427
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges.
Wang L; Dou M; Ma Q; Yao R; Liu J
Int Immunopharmacol; 2019 Sep; 74():105695. PubMed ID: 31254958
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cell-related anti-tumour adoptive cell immunotherapy.
Qi Y; Li Y; Wang H; Wang A; Liu X; Liang Z; Gao Y; Wei L
J Cell Mol Med; 2024 Jun; 28(11):e18362. PubMed ID: 38837666
[TBL] [Abstract][Full Text] [Related]
14. CAR-expressing NK cells for cancer therapy: a new hope.
Xia J; Minamino S; Kuwabara K
Biosci Trends; 2020 Nov; 14(5):354-359. PubMed ID: 32893255
[TBL] [Abstract][Full Text] [Related]
15. CAR-NK cell in cancer immunotherapy; A promising frontier.
Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
[TBL] [Abstract][Full Text] [Related]
16. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
17. The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells.
Moscarelli J; Zahavi D; Maynard R; Weiner LM
Transplant Cell Ther; 2022 Oct; 28(10):650-656. PubMed ID: 35788086
[TBL] [Abstract][Full Text] [Related]
18. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
Wang W; Jiang J; Wu C
Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
[TBL] [Abstract][Full Text] [Related]
19. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
Xiao L; Cen D; Gan H; Sun Y; Huang N; Xiong H; Jin Q; Su L; Liu X; Wang K; Yan G; Dong T; Wu S; Zhou P; Zhang J; Liang W; Ren J; Teng Y; Chen C; Xu XH
Mol Ther; 2019 Jun; 27(6):1114-1125. PubMed ID: 30962163
[TBL] [Abstract][Full Text] [Related]
20. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
